Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM Study)

Trial Profile

Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM Study)

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Allogeneic bone marrow derived mesenchymal stromal cell therapy Orbsen Therapeutics (Primary)
  • Indications Diabetic nephropathies
  • Focus Adverse reactions; First in man
  • Acronyms NEPHSTROM
  • Most Recent Events

    • 13 Nov 2017 Planned initiation date changed from 1 Jul 2017 to 1 Dec 2017.
    • 08 Aug 2017 New trial record
    • 02 Aug 2017 According to an Orbsen Therapeutics media release, OBRCEL-M, developed as part of NEPHSTROM, a European Union Horizon 2020-funded research project coordinated by NUI Galway, has been approved to begin testing.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top